787 related articles for article (PubMed ID: 15267123)
21. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.
McCloskey EV; Beneton M; Charlesworth D; Kayan K; deTakats D; Dey A; Orgee J; Ashford R; Forster M; Cliffe J; Kersh L; Brazier J; Nichol J; Aropuu S; Jalava T; Kanis JA
J Bone Miner Res; 2007 Jan; 22(1):135-41. PubMed ID: 17042717
[TBL] [Abstract][Full Text] [Related]
22. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G
Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
[TBL] [Abstract][Full Text] [Related]
23. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
24. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
25. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
26. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
[TBL] [Abstract][Full Text] [Related]
27. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
28. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Ozdemir F; Rodoplu M
Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
[TBL] [Abstract][Full Text] [Related]
29. Osteoporosis prevention and treatment.
Sambrook PN; Eisman JA
Med J Aust; 2000 Mar; 172(5):226-9. PubMed ID: 10776395
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic strategies for osteoporosis].
Chapurlat R; Delmas PD
Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
[TBL] [Abstract][Full Text] [Related]
31. Daily and cyclic parathyroid hormone in women receiving alendronate.
Cosman F; Nieves J; Zion M; Woelfert L; Luckey M; Lindsay R
N Engl J Med; 2005 Aug; 353(6):566-75. PubMed ID: 16093465
[TBL] [Abstract][Full Text] [Related]
32. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Martens MG
J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
[TBL] [Abstract][Full Text] [Related]
33. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.
Torregrosa JV; Fuster D; Gentil MA; Marcen R; Guirado L; Zarraga S; Bravo J; Burgos D; Monegal A; Muxí A; García S
Transplantation; 2010 Jun; 89(12):1476-81. PubMed ID: 20393402
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
35. Postmenopausal osteoporosis and alendronate.
Pérez-López FR
Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
[TBL] [Abstract][Full Text] [Related]
36. [Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Välimäki MJ
Duodecim; 2001; 117(24):2521-3. PubMed ID: 12183812
[No Abstract] [Full Text] [Related]
37. Management of osteoporosis due to ovarian failure.
Eastell R
Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
[TBL] [Abstract][Full Text] [Related]
38. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
39. Preventing osteoporotic fractures in older people.
McCloskey E
Practitioner; 2011 Jan; 255(1736):19-22, 2-3. PubMed ID: 21370710
[TBL] [Abstract][Full Text] [Related]
40. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
